<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004686</url>
  </required_header>
  <id_info>
    <org_study_id>199/13298</org_study_id>
    <secondary_id>CCF-RPC-4586</secondary_id>
    <secondary_id>CCF-FDR001040</secondary_id>
    <secondary_id>DPT-32-0-48</secondary_id>
    <nct_id>NCT00004686</nct_id>
  </id_info>
  <brief_title>Phase II Randomized Study of Glucocorticoids With or Without Methotrexate for Treatment of Giant Cell Arteritis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES: I. Compare the long term outcomes in patients with giant cell arteritis after&#xD;
      glucocorticoid treatment with or without methotrexate.&#xD;
&#xD;
      II. Compare remission relapse rates in these patients after glucocorticoid therapy with or&#xD;
      without methotrexate.&#xD;
&#xD;
      III. Determine whether adjunctive use of methotrexate lowers cumulative dose and duration of&#xD;
      glucocorticoid therapy and whether there is less treatment related morbidity and mortality.&#xD;
&#xD;
      IV. Demonstrate the feasibility of long term, double blind, placebo controlled, randomized,&#xD;
      multicenter trials for treatment of systemic vasculitides.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, double blind, multicenter study. Patients are&#xD;
      randomized into initial therapy with prednisone plus weekly placebo or prednisone plus weekly&#xD;
      oral methotrexate. Patients who do not respond to treatment within 5 days are taken off&#xD;
      study. If methotrexate toxicity dose not occur after 2 weeks, methotrexate is increased by&#xD;
      one tablet per week until a maximum tolerated dose (MTD) is achieved. The MTD of methotrexate&#xD;
      or the matching placebo dose is continued for 12 months in the absence of toxicity. Once 12&#xD;
      continuous months of remission are achieved, methotrexate or placebo is tapered to&#xD;
      discontinuation.&#xD;
&#xD;
      Patients are followed for 1-6 years.&#xD;
&#xD;
      Completion date provided represents the completion date of the grant per OOPD records&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1994</start_date>
  <completion_date>September 1999</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>300</enrollment>
  <condition>Giant Cell Arteritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:&#xD;
&#xD;
        --Disease Characteristics--&#xD;
&#xD;
        Diagnosis of giant cell arteritis (GCA) by at least one of the following:&#xD;
&#xD;
          -  Temporal artery biopsy confirming GCA Symptoms of GCA (including new onset (within 6&#xD;
             months) symptoms of headaches, tenderness of the scalp or the temporal arteries,&#xD;
             visual loss due to retinal ischemic optic neuropathy or otherwise unexplained tongue&#xD;
             or jaw pain) and an aortic angiogram that revealed stenotic and/or aneurysmal disease&#xD;
             of the aorta and its principal branches&#xD;
&#xD;
          -  Symptoms of polymyalgia rheumatica plus ischemic optic neuropathy, newly identified&#xD;
             tenderness over a temporal artery, or new onset of tongue or jaw pain&#xD;
&#xD;
        Westergren erythrocyte sedimentation rate of at least 40 nm in one hour&#xD;
&#xD;
        --Prior/Concurrent Therapy--&#xD;
&#xD;
        Endocrine therapy: No greater than 20 days since initiation of prednisone therapy&#xD;
&#xD;
        Other: No concurrent sulfa drugs or nonsteroidal antiinflammatory drugs&#xD;
&#xD;
        --Patient Characteristics--&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 4,000/mm3&#xD;
&#xD;
          -  Platelet count at least 120,000/mm3&#xD;
&#xD;
          -  No acute or chronic liver disease&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Alkaline phosphatase no greater than 2 times upper limit of normal&#xD;
&#xD;
          -  No other reproducible abnormal liver function test&#xD;
&#xD;
        Renal: Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No symptomatic peptic ulcer disease within the last 3 months&#xD;
&#xD;
          -  Hepatitis B or C antigen negative&#xD;
&#xD;
          -  No alcohol use in excess of 2 ounces of 100 proof liquor or 1 beer or its equivalent&#xD;
             per week&#xD;
&#xD;
          -  No insulin dependent diabetes mellitus plus morbid obesity (greater than 33% over&#xD;
             ideal body weight)&#xD;
&#xD;
          -  No recently (less than 6 months) diagnosed malignancy&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Adequate contraception required of all fertile patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Stuart Hoffman</last_name>
    <role>Study Chair</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <verification_date>March 1999</verification_date>
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>cardiovascular and respiratory diseases</keyword>
  <keyword>giant cell arteritis</keyword>
  <keyword>rare disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polymyalgia Rheumatica</mesh_term>
    <mesh_term>Giant Cell Arteritis</mesh_term>
    <mesh_term>Arteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

